Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Ulcerative Colitis: Update Bulletin #2 [March 2018]

Product Code:
596200962
Publication Date:
March 2018
Format:
PDF
Price:
$1,095

This edition presents key opinion leader (KOL) views on recent developments in the ulcerative colitis (UC) market. Topics covered include; Celgene reporting data from a Phase II trial of Otezla (apremilast) in patients with UC; Protalix BioTherapeutics announcing final dosing of the last patient in a Phase II trial evaluating OPRX 106, an oral anti-TNF, in patients with UC; and Pfizer announcing a positive outcome from a US Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee (GIDAC) meeting regarding Xeljanz (tofacitinib) for the treatment of moderate to severe UC.

Business Questions:

• According to KOLs, how clinically attractive is Otezla (apremilast) as a treatment for UC?
• What are the experts’ views on Otezla’s Phase II data?
• If approved, where would Otezla be positioned in the UC treatment paradigm?
• What do KOLs think of OPRX 106 as a therapy for UC?
• Do KOLs have any concerns regarding OPRX 106?
• What are KOLs’ reactions to the positive FDA outcome regarding Xeljanz (tofacitinib)?
• If approved, how is Xeljanz expected to be used in the UC treatment algorithm?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved